IGF1 and Hyperglycemia: These levels are substantially lower compared to the age-adjusted IGF-1 levels within the cohort investigated by Bourron, which ranged between less than 135 ng/mL in Q1 and higher than 283 ng/mL in Q4, although the study was also performed in ACS patients .14 Our data thus confirms the results of previous studies and extends them to current age ACS-treatment, indicating that ACS patients with hyperglycemia have lower levels of IGF-1, regardless of intervention strategy .17